Sphera Funds Management’s Xenon Pharmaceuticals XENE Stock Holding History

Sphera Funds Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.34M	Sell	105,000 -22,000	-17%	-$1.22M	0.83%	41
2026 Q1	$7.39M	Buy	+127,000	New	+$5.85M	1.17%	24
2025 Q2	–	Sell	-26,097	Closed	-$876K	–	135
2025 Q1	$876K	Sell	26,097 -26,000	-50%	-$987K	0.2%	95
2024 Q4	$2.04M	Buy	+52,097	New	+$2.15M	0.37%	81
2023 Q4	–	Sell	-38,959	Closed	-$1.33M	–	108
2023 Q3	$1.33M	Buy	+38,959	New	+$1.46M	0.24%	71
2021 Q4	–	Sell	-373,510	Closed	-$5.71M	–	127
2021 Q3	$5.71M	Buy	373,510 +97,380	+35%	+$1.69M	0.48%	61
2021 Q2	$51.4M	Buy	+276,130	New	+$5.09M	3.48%	6
2019 Q2	–	Sell	-533,655	Closed	-$5.42M	–	110
2019 Q1	$5.42M	Buy	533,655 +84,171	+19%	+$714K	0.49%	46
2018 Q4	$2.84M	Buy	449,484 +70,000	+18%	+$622K	0.32%	66
2018 Q3	$5.01M	Sell	379,484 -59,550	-14%	-$690K	0.58%	48
2018 Q2	$4.04M	Buy	+439,034	New	+$2.73M	0.56%	54
2017 Q4	–	Sell	-228,029	Closed	-$673K	–	154
2017 Q3	$673K	Hold	228,029	–	–	0.1%	108
2017 Q2	$718K	Sell	228,029 -100,000	-30%	-$391K	0.12%	109
2017 Q1	$1.31M	Hold	328,029	–	–	0.26%	87
2016 Q4	$2.53M	Buy	328,029 +100,000	+44%	+$803K	0.64%	48
2016 Q3	$1.85M	Buy	+228,029	New	+$1.76M	0.3%	75

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Sphera Funds Management's XENE Position: Q2 2026 in Review

Sphera Funds Management reduced its Xenon Pharmaceuticals (XENE) stake by 17% in Q2 2026, selling an estimated $1.22M and leaving 105,000 shares worth $6.34M. The position accounts for 0.83% of the portfolio, ranked #41.

Sphera Funds Management first reported a position in XENE in Q3 2016 and has held it in 16 quarters since. The position peaked at $51.4M in Q2 2021. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Sphera Funds Management held 105,000 shares of Xenon Pharmaceuticals worth $6.34M as of Q2 2026.
Sphera Funds Management sold 22,000 Xenon Pharmaceuticals shares in Q2 2026, an estimated $1.22M.
Xenon Pharmaceuticals made up 0.83% of Sphera Funds Management's portfolio in Q2 2026, its #41 holding.
Sphera Funds Management first reported a position in Xenon Pharmaceuticals in Q3 2016 and has held it in 16 quarters since.
Sphera Funds Management's Xenon Pharmaceuticals position peaked at $51.4M in Q2 2021.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.